Structure-based design of COX-2 selectivity into flurbiprofen
摘要:
Comparative computer modeling of the X-ray crystal structures of cyclooxygenase isoforms COX-1 and COX-2 has led to the design of COX-2 selectivity into the nonselective inhibitor flurbiprofen. The COX-2 modeling was based on a postulated binding mode for flurbiprofen and took advantage of a small alcove in the COX-2 active site created by different positions of the Leu384 sidechain between COX-I and COX-2. The design hypothesis was tested by synthesis and biological assay of a series of flurbiprofen analogs, culminating in the discovery of several inhibitors having up to 78-fold selectivity for COX-2 over COX-1. (C) 1999 Elsevier Science Ltd. All rights reserved.
BIARYL-ACETIC ACID DERIVATIVES AND THEIR USE AS COX-2 INHIBITORS
申请人:Merck Frosst Canada & Co.
公开号:EP1054857B1
公开(公告)日:2003-11-05
US5994379A
申请人:——
公开号:US5994379A
公开(公告)日:1999-11-30
Bisaryl COX-2 inhibiting compounds, compositions and methods of use
申请人:Merck Frosst Canada, Inc.
公开号:US05994379A1
公开(公告)日:1999-11-30
The present invention relates to inhibitors of COX-2, compositions which contain such compounds and methods of use. The compounds are represented by formula I: ##STR1## and include pharmaceutically acceptable salts and esters thereof.
Structure-based design of COX-2 selectivity into flurbiprofen
作者:Christopher I. Bayly、W.Cameron Black、Serge Léger、Nathalie Ouimet、Marc Ouellet、M.David Percival
DOI:10.1016/s0960-894x(98)00717-3
日期:1999.2
Comparative computer modeling of the X-ray crystal structures of cyclooxygenase isoforms COX-1 and COX-2 has led to the design of COX-2 selectivity into the nonselective inhibitor flurbiprofen. The COX-2 modeling was based on a postulated binding mode for flurbiprofen and took advantage of a small alcove in the COX-2 active site created by different positions of the Leu384 sidechain between COX-I and COX-2. The design hypothesis was tested by synthesis and biological assay of a series of flurbiprofen analogs, culminating in the discovery of several inhibitors having up to 78-fold selectivity for COX-2 over COX-1. (C) 1999 Elsevier Science Ltd. All rights reserved.